netFormulary Sunderland Joint Formulary NHS
NHS Sunderland Clinical Commissioning Group
City Hospitals Sunderland NHS Foundation Trust
 
 Search
 Formulary Chapter 12: Ear, nose and oropharynx - Full Chapter
12.03.05  Expand sub section  Treatment of dry mouth
12.03.05  Expand sub section  Local Treatment
Biotene Oralbalance
View adult BNF View SPC online
Formulary

Gel

 
   
BioXtra
View adult BNF View SPC online
Formulary

Gel: 40 mL
Spray: 50 mL
Mouth rinse: 250 mL      

 
   
Glandosane
View adult BNF View SPC online
Formulary

Spray

 
   
Orthana
View adult BNF View SPC online
Formulary  
   
Saliveze
View adult BNF View SPC online
Formulary  
   
Salivix
View adult BNF View SPC online
Formulary  
   
Xerotin
View adult BNF View SPC online
Formulary

Spray (sugar-free):100 mL

 
   
Aequasyal
View adult BNF View SPC online
Formulary

By initiation of head and neck specialist only (2nd or 3rd line for patients undergoing radiotherapy)

 
   
12.03.05  Expand sub section  Systemic treatment
 ....
 Non Formulary Items
Luborant

View adult BNF View SPC online
Non Formulary
 
Salinum

View adult BNF View SPC online
Non Formulary
 
SST

View adult BNF View SPC online
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist. These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.   

Amber

These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

Green +

Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. An information leaflet may be provided in order to facilitate ongoing prescribing in primary care.   

Green

These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.   

netFormulary